Last reviewed · How we verify
A Phase I Study of MK2206 in Patients With Locally Advanced or Metastatic Solid Tumors
This study is designed to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of MK2206 when administered with Every Other Day (QOD) and Once Weekly (QW) dosing schedules.
Details
| Lead sponsor | Merck Sharp & Dohme LLC |
|---|---|
| Phase | Phase 1 |
| Status | COMPLETED |
| Enrolment | 24 |
| Start date | 2010-02 |
| Completion | 2011-09 |
Conditions
- Solid Tumors
Interventions
- MK2206 every other day
- MK2206 once weekly
Primary outcomes
- Characterize safety and tolerability of MK2206 by monitoring incidence of protocol-defined dose limiting toxicities (DLTs) — Day 1 - Day 28 (Cycle 1)